Successful Management of an Oligometastatic Nsclc Patient with Multimodal Therapy

Non-small cell lung cancer (NSCLC) is more often diagnosed at an advanced stage and carries a poor prognosis. Recently, according to the new version of AJCC staging system published in 2018, oligometastatic disease has been integrated as an intermediate stage between non-metastatic and metastatic forms. The prognosis of oligometastatic NSCLC was significantly improved by the use of multimodal therapy, including chemotherapy, targeted therapies, immunotherapy, surgery and stereotactic radiotherapy. However, there is little evidence regarding the optimal sequence of these modalities in the management of patients with oligometastatic disease. We describe here a case study of a patient diagnosed with metachronous oligometastatic NSCLC, successfully managed by multimodal therapy based on stereotactic radiotherapy, chemotherapy, immunotherapy and standard radiotherapy for local control. Furthermore, randomized prospective studies would be of capital interest, including multi-centre patient studies and evaluation of several treatment strategies.